Botanical-drug interactions: A scientific perspective

Planta Medica

Volumn 78, Issue 13, 2012, Pages 1400-1415

  De Lima Toccafondo Vieira, Manuela ^a   Huang, Shiew Mei ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

botanical products; clinical pharmacology; drug interactions; regulatory science

Indexed keywords

ALKALOID; AURANTIIN; BERGAMOTTIN; CYCLOSPORIN; DIGOXIN; ECHINACEA EXTRACT; GARLIC EXTRACT; GINKGO BILOBA EXTRACT; GINSENG EXTRACT; HERBACEOUS AGENT; HYPERICUM PERFORATUM EXTRACT; PLANT EXTRACT; WARFARIN;

DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG INTERACTION; DRUG METABOLISM; FOOD DRUG INTERACTION; GRAPE JUICE; HUMAN; HYDRASTIS; NONHUMAN; REVIEW;

DRUG LABELING; DRUG SYNERGISM; ENZYME INHIBITORS; HERB-DRUG INTERACTIONS; HUMANS; ORGANIC ANION TRANSPORTERS; PHARMACOKINETICS; PLANT PREPARATIONS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84866085375     PISSN: 00320943     EISSN: 14390221     Source Type: Journal    
DOI: 10.1055/s-0032-1315145     Document Type: Review

References (202)

1. American Botanical Council Herbal supplements sale rise in all channels in 2009. Herbalgram: 2010; 86 62 65
2. Bardia A, Nisly NL, Zimmerman MB, Gryzlak BM, Wallace RB. Use of herbs among adults based on evidence-based indications: findings from the National Health Interview Survey. Mayo Clin Proc: 2007; 82 561 566
3. Bent S. Herbal medicine in the United States: review of efficacy, safety, and regulation: grand rounds at University of California, San Francisco Medical Center. J Gen Intern Med: 2008; 23 854 859
4. Hensrud DD, Engle DD, Scheitel SM. Underreporting the use of dietary supplements and nonprescription medications among patients undergoing a periodic health examination. Mayo Clin Proc: 1999; 74 443 447
5. Ernst E. Herb-drug interactions: potentially important but woefully under-researched. Eur J Clin Pharmacol: 2000; 56 523 524
6. Dodge T, Litt D, Kaufman A. Influence of the dietary supplement health and education act on consumer beliefs about the safety and effectiveness of dietary supplements. J Health Commun: 2011; 16 230 244
7. Fugh-Berman A. Herb-drug interactions. Lancet: 2000; 355 134 138
8. Ruschitzka F, Meier PJ, Turina M, Luscher TF, Noll G. Acute heart transplant rejection due to Saint Johns wort. Lancet: 2000; 355 548 549
9. Mathijssen RH, Verweij J, de Bruijn P, Loos WJ, Sparreboom A. Effects of St. Johns wort on irinotecan metabolism. J Natl Cancer Inst: 2002; 94 1247 1249
10. Zhou SF, Zhou ZW, Li CG, Chen X, Yu X, Xue CC, Herington A. Identification of drugs that interact with herbs in drug development. Drug Discov Today: 2007; 12 664 673
11. Wienkers LC, Heath TG. Predicting in vivo drug interactions from in vitro drug discovery data. Nat Rev Drug Discov: 2005; 4 825 833
12. Lam Y, Huang SM, Hall SD. Drug interactions with botanical products. In: Lam Y, Huang S, Hall S. editors Herbal supplements-drug interactions - Scientific and regulatory perspectives. Drugs and the pharmaceutical sciences. New York Taylor & Francis: 2006; 25 47
13. Guillemette C. Pharmacogenomics of human UDP-glucuronosyltransferase enzymes. Pharmacogenomics J: 2003; 3 136 158
14. Obach RS, Walsky RL, Venkatakrishnan K. Mechanism-based inactivation of human cytochrome p 450 enzymes and the prediction of drug-drug interactions. Drug Metab Dispos: 2007; 35 246 255
15. Zhou S, Koh HL, Gao Y, Gong ZY, Lee EJ. Herbal bioactivation: the good, the bad and the ugly. Life Sci: 2004; 74 935 968
16. Tarirai C, Viljoen AM, Hamman JH. Herb-drug pharmacokinetic interactions reviewed. Expert Opin Drug Metab Toxicol: 2010; 6 1515 1538
17. Sridar C, Goosen TC, Kent UM, Williams JA, Hollenberg PF. Silybin inactivates cytochromes P450 3A4 and 2C9 and inhibits major hepatic glucuronosyltransferases. Drug Metab Dispos: 2004; 32 587 594
18. Tassaneeyakul W, Guo LQ, Fukuda K, Ohta T, Yamazoe Y. Inhibition selectivity of grapefruit juice components on human cytochromes P450. Arch Biochem Biophys: 2000; 378 356 363
19. Guo LQ, Yamazoe Y. Inhibition of cytochrome P450 by furanocoumarins in grapefruit juice and herbal medicines. Acta Pharmacol Sin: 2004; 25 129 136
20. Schmiedlin-Ren P, Edwards DJ, Fitzsimmons ME, He K, Lown KS, Woster PM, Rahman A, Thummel KE, Fisher JM, Hollenberg PF, Watkins PB. Mechanisms of enhanced oral availability of CYP3A4 substrates by grapefruit constituents. Decreased enterocyte CYP3A4 concentration and mechanism-based inactivation by furanocoumarins. Drug Metab Dispos: 1997; 25 1228 1233
21. Lown KS, Bailey DG, Fontana RJ, Janardan SK, Adair CH, Fortlage LA, Brown MB, Guo W, Watkins PB. Grapefruit juice increases felodipine oral availability in humans by decreasing intestinal CYP3A protein expression. J Clin Invest: 1997; 99 2545 2553
22. Hanley MJ, Cancalon P, Widmer WW, Greenblatt DJ. The effect of grapefruit juice on drug disposition. Expert Opin Drug Metab Toxicol: 2011; 7 267 286
23. Xin HW, Wu XC, Li Q, Yu AR, Zhong MY, Liu YY. The effects of berberine on the pharmacokinetics of cyclosporin A in healthy volunteers. Methods Find Exp Clin Pharmacol: 2006; 28 25 29
24. Wu X, Li Q, Xin H, Yu A, Zhong M. Effects of berberine on the blood concentration of cyclosporin A in renal transplanted recipients: clinical and pharmacokinetic study. Eur J Clin Pharmacol: 2005; 61 567 572
25. Foster BC, Vandenhoek S, Hana J, Krantis A, Akhtar MH, Bryan M, Budzinski JW, Ramputh A, Arnason JT. In vitro inhibition of human cytochrome P450-mediated metabolism of marker substrates by natural products. Phytomedicine: 2003; 10 334 342
26. Raner GM, Cornelious S, Moulick K, Wang Y, Mortenson A, Cech NB. Effects of herbal products and their constituents on human cytochrome P450(2E1) activity. Food Chem Toxicol: 2007; 45 2359 2365
27. Etheridge AS, Black SR, Patel PR, So J, Mathews JM. An in vitro evaluation of cytochrome P450 inhibition and P-glycoprotein interaction with goldenseal, Ginkgo biloba, grape seed, milk thistle, and ginseng extracts and their constituents. Planta Med: 2007; 73 731 741
28. Budzinski JW, Trudeau VL, Drouin CE, Panahi M, Arnason JT, Foster BC. Modulation of human cytochrome P450 3A4 (CYP3A4) and P-glycoprotein (P-gp) in Caco-2 cell monolayers by selected commercial-source milk thistle and goldenseal products. Can J Physiol Pharmacol: 2007; 85 966 978
29. Gurley BJ, Gardner SF, Hubbard MA, Williams DK, Gentry WB, Khan IA, Shah A. In vivo effects of goldenseal, kava kava, black cohosh, and valerian on human cytochrome P450 1A2, 2D6, 2E1, and 3A4/5 phenotypes. Clin Pharmacol Ther: 2005; 77 415 426
30. Gurley BJ, Swain A, Hubbard MA, Williams DK, Barone G, Hartsfield F, Tong Y, Carrier DJ, Cheboyina S, Battu SK. Clinical assessment of CYP2D6-mediated herb-drug interactions in humans: effects of milk thistle, black cohosh, goldenseal, kava kava, St. Johns wort, and Echinacea. Mol Nutr Food Res: 2008; 52 755 763
31. Gurley BJ, Swain A, Hubbard MA, Hartsfield F, Thaden J, Williams DK, Gentry WB, Tong Y. Supplementation with goldenseal (Hydrastis canadensis), but not kava kava (Piper methysticum), inhibits human CYP3A activity in vivo. Clin Pharmacol Ther: 2008; 83 61 69
32. Hewitt NJ, Lecluyse EL, Ferguson SS. Induction of hepatic cytochrome P450 enzymes: methods, mechanisms, recommendations, and in vitro - in vivo correlations. Xenobiotica: 2007; 37 1196 1224
33. di Masi A, De Marinis E, Ascenzi P, Marino M. Nuclear receptors CAR and PXR: Molecular, functional, and biomedical aspects. Mol Aspects Med: 2009; 30 297 343
34. Komoroski BJ, Zhang S, Cai H, Hutzler JM, Frye R, Tracy TS, Strom SC, Lehmann T, Ang CY, Cui YY, Venkataramanan R. Induction and inhibition of cytochromes P450 by the St. Johns wort constituent hyperforin in human hepatocyte cultures. Drug Metab Dispos: 2004; 32 512 518
35. Moore LB, Goodwin B, Jones SA, Wisely GB, Serabjit-Singh CJ, Willson TM, Collins JL, Kliewer SA. St. Johns wort induces hepatic drug metabolism through activation of the pregnane X receptor. Proc Natl Acad Sci USA: 2000; 97 7500 7502
36. Kober M, Pohl K, Efferth T. Molecular mechanisms underlying St. Johns wort drug interactions. Curr Drug Metab: 2008; 9 1027 1037
37. Wentworth JM, Agostini M, Love J, Schwabe JW, Chatterjee VK. St Johns wort, a herbal antidepressant, activates the steroid X receptor. J Endocrinol: 2000; 166 R11 R16
38. de Maat MM, Hoetelmans RM, Math t RA, van Gorp EC, Meenhorst PL, Mulder JW, Beijnen JH. Drug interaction between St Johns wort and nevirapine. AIDS: 2001; 15 420 421
39. Portoles A, Terleira A, Calvo A, Martinez I, Resplandy G. Effects of Hypericum perforatum on ivabradine pharmacokinetics in healthy volunteers: an open-label, pharmacokinetic interaction clinical trial. J Clin Pharmacol: 2006; 46 1188 1194
40. Kawaguchi A, Ohmori M, Tsuruoka S, Nishiki K, Harada K, Miyamori I, Yano R, Nakamura T, Masada M, Fujimura A. Drug interaction between St Johns Wort and quazepam. Br J Clin Pharmacol: 2004; 58 403 410
41. Tannergren C, Engman H, Knutson L, Hedeland M, Bondesson U, Lennernas H. St Johns wort decreases the bioavailability of R- and S-verapamil through induction of the first-pass metabolism. Clin Pharmacol Ther: 2004; 75 298 309
42. Jiang X, Williams KM, Liauw WS, Ammit AJ, Roufogalis BD, Duke CC, Day RO, McLachlan AJ. Effect of St Johns wort and ginseng on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects. Br J Clin Pharmacol: 2004; 57 592 599
43. Hellum BH, Hu Z, Nilsen OG. Trade herbal products and induction of CYP2C19 and CYP2E1 in cultured human hepatocytes. Basic Clin Pharmacol Toxicol: 2009; 105 58 63
44. Karyekar CS, Eddington ND, Dowling TC. Effect of St. Johns Wort extract on intestinal expression of cytochrome P4501A2: studies in LS180 cells. J Postgrad Med: 2002; 48 97 100
45. Gurley BJ, Gardner SF, Hubbard MA, Williams DK, Gentry WB, Cui Y, Ang CY. Clinical assessment of effects of botanical supplementation on cytochrome P450 phenotypes in the elderly: St Johns wort, garlic oil, Panax ginseng and Ginkgo biloba. Drugs Aging: 2005; 22 525 539
46. Gurley BJ, Gardner SF, Hubbard MA, Williams DK, Gentry WB, Cui Y, Ang CY. Cytochrome P450 phenotypic ratios for predicting herb-drug interactions in humans. Clin Pharmacol Ther: 2002; 72 276 287
47. Wang LS, Zhu B, Abd El-Aty AM, Zhou G, Li Z, Wu J, Chen GL, Liu J, Tang ZR, An W, Li Q, Wang D, Zhou HH. The influence of St Johns Wort on CYP2C19 activity with respect to genotype. J Clin Pharmacol: 2004; 44 577 581
48. Wang LS, Zhou G, Zhu B, Wu J, Wang JG, Abd El-Aty AM, Li T, Liu J, Yang TL, Wang D, Zhong XY, Zhou HH. St Johns wort induces both cytochrome P450 3A4-catalyzed sulfoxidation and 2C19-dependent hydroxylation of omeprazole. Clin Pharmacol Ther: 2004; 75 191 197
49. Xu H, Williams KM, Liauw WS, Murray M, Day RO, McLachlan AJ. Effects of St Johns wort and CYP2C9 genotype on the pharmacokinetics and pharmacodynamics of gliclazide. Br J Pharmacol: 2008; 153 1579 1586
50. Wang Z, Gorski JC, Hamman MA, Huang SM, Lesko LJ, Hall SD. The effects of St Johns wort (Hypericum perforatum) on human cytochrome P450 activity. Clin Pharmacol Ther: 2001; 70 317 326
51. Arold G, Donath F, Maurer A, Diefenbach K, Bauer S, Henneicke-von Zepelin HH, Friede M, Roots I. No relevant interaction with alprazolam, caffeine, tolbutamide, and digoxin by treatment with a low-hyperforin St Johns wort extract. Planta Med: 2005; 71 331 337
52. Wenk M, Todesco L, Krahenbuhl S. Effect of St Johns wort on the activities of CYP1A2, CYP3A4, CYP2D6, N-acetyltransferase 2, and xanthine oxidase in healthy males and females. Br J Clin Pharmacol: 2004; 57 495 499
53. Nebel A, Schneider BJ, Baker RK, Kroll DJ. Potential metabolic interaction between St. Johns wort and theophylline. Ann Pharmacother: 1999; 33 502
54. de los Reyes GC, Koda RT. Determining hyperforin and hypericin content in eight brands of St. Johns wort. Am J Health Syst Pharm: 2002; 59 545 547
55. Krochmal R, Hardy M, Bowerman S, Lu QY, Wang HJ, Elashoff R, Heber D. Phytochemical assays of commercial botanical dietary supplements. Evid Based Complement Alternat Med: 2004; 1 305 313
56. Obach RS. Inhibition of human cytochrome P450 enzymes by constituents of St. Johns Wort, an herbal preparation used in the treatment of depression. J Pharmacol Exp Ther: 2000; 294 88 95
57. Hellum BH, Nilsen OG. The in vitro inhibitory potential of trade herbal products on human CYP2D6-mediated metabolism and the influence of ethanol. Basic Clin Pharmacol Toxicol: 2007; 101 350 358
58. Rengelshausen J, Banfield M, Riedel KD, Burhenne J, Weiss J, Thomsen T, Walter-Sack I, Haefeli WE, Mikus G. Opposite effects of short-term and long-term St Johns wort intake on voriconazole pharmacokinetics. Clin Pharmacol Ther: 2005; 78 25 33
59. Mohutsky MA, Anderson GD, Miller JW, Elmer GW. Ginkgo biloba: evaluation of CYP2C9 drug interactions in vitro and in vivo. Am J Ther: 2006; 13 24 31
60. Jiang X, Williams KM, Liauw WS, Ammit AJ, Roufogalis BD, Duke CC, Day RO, McLachlan AJ. Effect of ginkgo and ginger on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects. Br J Clin Pharmacol: 2005; 59 425 432
61. Kim BH, Kim KP, Lim KS, Kim JR, Yoon SH, Cho JY, Lee YO, Lee KH, Jang IJ, Shin SG, Yu KS. Influence of Ginkgo biloba extract on the pharmacodynamic effects and pharmacokinetic properties of ticlopidine: an open-label, randomized, two-period, two-treatment, two-sequence, single-dose crossover study in healthy Korean male volunteers. Clin Ther: 2010; 32 380 390
62. Uchida S, Yamada H, Li XD, Maruyama S, Ohmori Y, Oki T, Watanabe H, Umegaki K, Ohashi K, Yamada S. Effects of Ginkgo biloba extract on pharmacokinetics and pharmacodynamics of tolbutamide and midazolam in healthy volunteers. J Clin Pharmacol: 2006; 46 1290 1298
63. Liu XP, Goldring CE, Wang HY, Copple IM, Kitteringham NR, Park BK. Extract of Ginkgo biloba induces glutathione-S-transferase subunit-P1 in vitro. Phytomedicine: 2009; 16 451 455
64. Sugiyama T, Kubota Y, Shinozuka K, Yamada S, Yamada K, Umegaki K. Induction and recovery of hepatic drug metabolizing enzymes in rats treated with Ginkgo biloba extract. Food Chem Toxicol: 2004; 42 953 957
65. Mohamed MF, Frye RF. Inhibition of intestinal and hepatic glucuronidation of mycophenolic acid by Ginkgo biloba extract and flavonoids. Drug Metab Dispos: 2010; 38 270 275
66. van Erp NP, Baker SD, Zhao M, Rudek MA, Guchelaar HJ, Nortier JW, Sparreboom A, Gelderblom H. Effect of milk thistle (Silybum marianum) on the pharmacokinetics of irinotecan. Clin Cancer Res: 2005; 11 7800 7806
67. Marchetti S, Mazzanti R, Beijnen JH, Schellens JH. Concise review: Clinical relevance of drug drug and herb drug interactions mediated by the ABC transporter ABCB1 (MDR1, P-glycoprotein). Oncologist: 2007; 12 927 941
68. Matic M, Mahns A, Tsoli M, Corradin A, Polly P, Robertson GR. Pregnane X receptor: promiscuous regulator of detoxification pathways. Int J Biochem Cell Biol: 2007; 39 478 483
69. Dasgupta A. Herbal supplements and therapeutic drug monitoring: focus on digoxin immunoassays and interactions with St. Johns wort. Ther Drug Monit: 2008; 30 212 217
70. Mueller SC, Uehleke B, Woehling H, Petzsch M, Majcher-Peszynska J, Hehl EM, Sievers H, Frank B, Riethling AK, Drewelow B. Effect of St Johns wort dose and preparations on the pharmacokinetics of digoxin. Clin Pharmacol Ther: 2004; 75 546 557
71. Schwarz UI, Hanso H, Oertel R, Miehlke S, Kuhlisch E, Glaeser H, Hitzl M, Dresser GK, Kim RB, Kirch W. Induction of intestinal P-glycoprotein by St Johns wort reduces the oral bioavailability of talinolol. Clin Pharmacol Ther: 2007; 81 669 678
72. Wang Z, Hamman MA, Huang SM, Lesko LJ, Hall SD. Effect of St Johns wort on the pharmacokinetics of fexofenadine. Clin Pharmacol Ther: 2002; 71 414 420
73. Tian R, Koyabu N, Morimoto S, Shoyama Y, Ohtani H, Sawada Y. Functional induction and de-induction of P-glycoprotein by St. Johns wort and its ingredients in a human colon adenocarcinoma cell line. Drug Metab Dispos: 2005; 33 547 554
74. Gutmann H, Poller B, Buter KB, Pfrunder A, Schaffner W, Drewe J. Hypericum perforatum: which constituents may induce intestinal MDR1 and CYP3A4 mRNA expression? Planta Med: 2006; 72 685 690
75. Durr D, Stieger B, Kullak-Ublick GA, Rentsch KM, Steinert HC, Meier PJ, Fattinger K. St Johns Wort induces intestinal P-glycoprotein/MDR1 and intestinal and hepatic CYP3A4. Clin Pharmacol Ther: 2000; 68 598 604
76. Fan L, Mao XQ, Tao GY, Wang G, Jiang F, Chen Y, Li Q, Zhang W, Lei HP, Hu DL, Huang YF, Wang D, Zhou HH. Effect of Schisandra chinensis extract and Ginkgo biloba extract on the pharmacokinetics of talinolol in healthy volunteers. Xenobiotica: 2009; 39 249 254
77. Fan L, Tao GY, Wang G, Chen Y, Zhang W, He YJ, Li Q, Lei HP, Jiang F, Hu DL, Huang YF, Zhou HH. Effects of Ginkgo biloba extract ingestion on the pharmacokinetics of talinolol in healthy Chinese volunteers. Ann Pharmacother: 2009; 43 944 949
78. Mauro VF, Mauro LS, Kleshinski JF, Khuder SA, Wang Y, Erhardt PW. Impact of Ginkgo biloba on the pharmacokinetics of digoxin. Am J Ther: 2003; 10 247 251
79. Robertson SM, Davey RT, Voell J, Formentini E, Alfaro RM, Penzak SR. Effect of Ginkgo biloba extract on lopinavir, midazolam and fexofenadine pharmacokinetics in healthy subjects. Curr Med Res Opin: 2008; 24 591 599
80. Hellum BH, Nilsen OG. In vitro inhibition of CYP3A4 metabolism and P-glycoprotein-mediated transport by trade herbal products. Basic Clin Pharmacol Toxicol: 2008; 102 466 475
81. Wang Y, Cao J, Zeng S. Involvement of P-glycoprotein in regulating cellular levels of Ginkgo flavonols: quercetin, kaempferol, and isorhamnetin. J Pharm Pharmacol: 2005; 57 751 758
82. Fuchikami H, Satoh H, Tsujimoto M, Ohdo S, Ohtani H, Sawada Y. Effects of herbal extracts on the function of human organic anion-transporting polypeptide OATP-B. Drug Metab Dispos: 2006; 34 577 582
83. Satoh H, Yamashita F, Tsujimoto M, Murakami H, Koyabu N, Ohtani H, Sawada Y. Citrus juices inhibit the function of human organic anion-transporting polypeptide OATP-B. Drug Metab Dispos: 2005; 33 518 523
84. Wang X, Wolkoff AW, Morris ME. Flavonoids as a novel class of human organic anion-transporting polypeptide OATP1B1 (OATP-C) modulators. Drug Metab Dispos: 2005; 33 1666 1672
85. Bailey DG, Dresser GK, Leake BF, Kim RB. Naringin is a major and selective clinical inhibitor of organic anion-transporting polypeptide 1A2 (OATP1A2) in grapefruit juice. Clin Pharmacol Ther: 2007; 81 495 502
86. Alscher DM, Klotz U. Drug interaction of herbal tea containing St. Johns wort with cyclosporine. Transpl Int: 2003; 16 543 544
87. Bauer S, Stormer E, Johne A, Kruger H, Budde K, Neumayer HH, Roots I, Mai I. Alterations in cyclosporin A pharmacokinetics and metabolism during treatment with St Johns wort in renal transplant patients. Br J Clin Pharmacol: 2003; 55 203 211
88. Frye RF, Fitzgerald SM, Lagattuta TF, Hruska MW, Egorin MJ. Effect of St Johns wort on imatinib mesylate pharmacokinetics. Clin Pharmacol Ther: 2004; 76 323 329
89. Smith P, Bullock JM, Booker BM, Haas CE, Berenson CS, Jusko WJ. The influence of St. Johns wort on the pharmacokinetics and protein binding of imatinib mesylate. Pharmacotherapy: 2004; 24 1508 1514
90. Piscitelli SC, Burstein AH, Chaitt D, Alfaro RM, Falloon J. Indinavir concentrations and St Johns wort. Lancet: 2000; 355 547 548
91. Sugimoto K, Ohmori M, Tsuruoka S, Nishiki K, Kawaguchi A, Harada K, Arakawa M, Sakamoto K, Masada M, Miyamori I, Fujimura A. Different effects of St Johns wort on the pharmacokinetics of simvastatin and pravastatin. Clin Pharmacol Ther: 2001; 70 518 524
92. Di YM, Li CG, Xue CC, Zhou SF. Clinical drugs that interact with St. Johns wort and implication in drug development. Curr Pharm Des: 2008; 14 1723 1742
93. Borrelli F, Izzo AA. Herb-drug interactions with St Johns wort (Hypericum perforatum): an update on clinical observations. AAPS J: 2009; 11 710 727
94. Zhang L, Zhang Y, Huang SM. Scientific and regulatory perspectives on metabolizing enzyme-transporter interplay and its role in drug interactions: challenges in predicting drug interactions. Mol Pharm: 2009; 6 1766 1774
95. Patel J, Buddha B, Dey S, Pal D, Mitra AK. In vitro interaction of the HIV protease inhibitor ritonavir with herbal constituents: changes in P-gp and CYP3A4 activity. Am J Ther: 2004; 11 262 277
96. Nabekura T, Kamiyama S, Kitagawa S. Effects of dietary chemopreventive phytochemicals on P-glycoprotein function. Biochem Biophys Res Commun: 2005; 327 866 870
97. Piscitelli SC, Burstein AH, Welden N, Gallicano KD, Falloon J. The effect of garlic supplements on the pharmacokinetics of saquinavir. Clin Infect Dis: 2002; 34 234 238
98. Hajda J, Rentsch KM, Gubler C, Steinert H, Stieger B, Fattinger K. Garlic extract induces intestinal P-glycoprotein, but exhibits no effect on intestinal and hepatic CYP3A4 in humans. Eur J Pharm Sci: 2010; 41 729 735
99. Gallicano K, Foster B, Choudhri S. Effect of short-term administration of garlic supplements on single-dose ritonavir pharmacokinetics in healthy volunteers. Br J Clin Pharmacol: 2003; 55 199 202
100. Berginc K, Trontelj J, Kristl A. The influence of aged garlic extract on the uptake of saquinavir and darunavir into HepG2 cells and rat liver slices. Drug Metab Pharmacokinet: 2010; 25 307 313
101. Berginc K, Milisav I, Kristl A. Garlic flavonoids and organosulfur compounds: impact on the hepatic pharmacokinetics of saquinavir and darunavir. Drug Metab Pharmacokinet: 2010; 25 521 530
102. Dalvi RR. Alterations in hepatic phase I and phase II biotransformation enzymes by garlic oil in rats. Toxicol Lett: 1992; 60 299 305
103. Wu CC, Sheen LY, Chen HW, Kuo WW, Tsai SJ, Lii CK. Differential effects of garlic oil and its three major organosulfur components on the hepatic detoxification system in rats. J Agric Food Chem: 2002; 50 378 383
104. Chang TK. Activation of pregnane X receptor (PXR) and constitutive androstane receptor (CAR) by herbal medicines. AAPS J: 2009; 11 590 601
105. Ho BE, Shen DD, McCune JS, Bui T, Risler L, Yang Z, Ho RJ. Effects of garlic on cytochromes P450 2C9- and 3A4-mediated drug metabolism in human hepatocytes. Sci Pharm: 2010; 78 473 481
106. Lawson LD, Wang ZJ, Hughes BG. Identification and HPLC quantitation of the sulfides and dialk(en)yl thiosulfinates in commercial garlic products. Planta Med: 1991; 57 363 370
107. Lawson LD, Gardner CD. Composition, stability, and bioavailability of garlic products used in a clinical trial. J Agric Food Chem: 2005; 53 6254 6261
108. Saw JT, Bahari MB, Ang HH, Lim YH. Potential drug-herb interaction with antiplatelet/anticoagulant drugs. Complement Ther Clin Pract: 2006; 12 236 241
109. Chung KF, Dent G, McCusker M, Guinot P, Page CP, Barnes PJ. Effect of a ginkgolide mixture (BN 52063) in antagonising skin and platelet responses to platelet activating factor in man. Lancet: 1987; 1 248 251
110. [No authors listed] Haemorrhage due to Ginkgo biloba ? Prescrire Int: 2008; 17 19
111. Bone KM. Potential interaction of Ginkgo biloba leaf with antiplatelet or anticoagulant drugs: what is the evidence? Mol Nutr Food Res: 2008; 52 764 771
112. Engelsen J, Nielsen JD, Winther K. Effect of coenzyme Q10 and Ginkgo biloba on warfarin dosage in stable, long-term warfarin treated outpatients. A randomised, double blind, placebo-crossover trial. Thromb Haemost: 2002; 87 1075 1076
113. Gardner CD, Zehnder JL, Rigby AJ, Nicholus JR, Farquhar JW. Effect of Ginkgo bilob a (EGb 761) and aspirin on platelet aggregation and platelet function analysis among older adults at risk of cardiovascular disease: a randomized clinical trial. Blood Coagul Fibrinolysis: 2007; 18 787 793
114. Aruna D, Naidu MU. Pharmacodynamic interaction studies of Ginkgo biloba with cilostazol and clopidogrel in healthy human subjects. Br J Clin Pharmacol: 2007; 63 333 338
115. Biber A. Pharmacokinetics of Ginkgo biloba extracts. Pharmacopsychiatry: 2003; 36 01 S32 S37
116. Koch E. Inhibition of platelet activating factor (PAF)-induced aggregation of human thrombocytes by ginkgolides: considerations on possible bleeding complications after oral intake of Ginkgo biloba extracts. Phytomedicine: 2005; 12 10 16
117. [no authors listed] Summaries for patients: ginseng reduces the effect of warfarin in a study of healthy volunteers. Ann Intern Med: 2004; 141 158
118. Lee SH, Ahn YM, Ahn SY, Doo HK, Lee BC. Interaction between warfarin and Panax ginseng in ischemic stroke patients. J Altern Complement Med: 2008; 14 715 721
119. Lee YH, Lee BK, Choi YJ, Yoon IK, Chang BC, Gwak HS. Interaction between warfarin and Korean red ginseng in patients with cardiac valve replacement. Int J Cardiol: 2010; 145 275 276
120. Yuan CS, Wei G, Dey L, Karrison T, Nahlik L, Maleckar S, Kasza K, Ang-Lee M, Moss J. Brief communication: American ginseng reduces warfarins effect in healthy patients: a randomized, controlled trial. Ann Intern Med: 2004; 141 23 27
121. Qi LW, Wang CZ, Yuan CS. Ginsenosides from American ginseng: chemical and pharmacological diversity. Phytochemistry: 2011; 72 689 699
122. Legnani C, Frascaro M, Guazzaloca G, Ludovici S, Cesarano G, Coccheri S. Effects of a dried garlic preparation on fibrinolysis and platelet aggregation in healthy subjects. Arzneimittelforschung: 1993; 43 119 122
123. Sunter W. Warfarin and garlic. Pharm J: 1991; 246 722
124. Page RL, Lawrence JD. Potentiation of warfarin by dong quai. Pharmacotherapy: 1999; 19 870 876
125. Lau WC, Welch TD, Shields T, Rubenfire M, Tantry US, Gurbel PA. The effect of St Johns Wort on the pharmacodynamic response of clopidogrel in hyporesponsive volunteers and patients: increased platelet inhibition by enhancement of CYP3A4 metabolic activity. J Cardiovasc Pharmacol: 2011; 57 86 93
126. Spigset O. Reduced effect of warfarin caused by ubidecarenone. Lancet: 1994; 344 1372 1373
127. Bristol-Myers Squibb Company COUMADIN (warfarin sodium) tablets. Drug Label. Available at http://www.accessdata.fda.gov/drugsatfda-docs/label/2011/ 009218s107lbl.pdf Accessed April 20, 2012
128. Shelton RC. St Johns wort (Hypericum perforatum) in major depression. J Clin Psychiatry: 2009; 70 05 23 27
129. Barbenel DM, Yusufi B, OShea D, Bench CJ. Mania in a patient receiving testosterone replacement postorchidectomy taking St Johns wort and sertraline. J Psychopharmacol: 2000; 14 84 86
130. Bonetto N, Santelli L, Battistin L, Cagnin A. Serotonin syndrome and rhabdomyolysis induced by concomitant use of triptans, fluoxetine and hypericum. Cephalalgia: 2007; 27 1421 1423
131. Gordon JB. SSRIs and St. Johns Wort: possible toxicity? Am Fam Physician: 1998; 57 950 953
132. Lantz MS, Buchalter E, Giambanco V. St. Johns wort and antidepressant drug interactions in the elderly. J Geriatr Psychiatry Neurol: 1999; 12 7 10
133. Dannawi M. Possible serotonin syndrome after combination of buspirone and St Johns Wort. J Psychopharmacol: 2002; 16 401
134. Nathan PJ. Hypericum perforatum (St Johns Wort): a non-selective reuptake inhibitor? A review of the recent advances in its pharmacology. J Psychopharmacol: 2001; 15 47 54
135. Schelosky L, Raffauf C, Jendroska K, Poewe W. Kava and dopamine antagonism. J Neurol Neurosurg Psychiatry: 1995; 58 639 640
136. Sarris J, LaPorte E, Schweitzer I. Kava: a comprehensive review of efficacy, safety, and psychopharmacology. Aust NZ J Psychiatry: 2011; 45 27 35
137. Zou L, Henderson GL, Harkey MR, Sakai Y, Li A. Effects of kava (Kava-kava, Awa, Yaqona, Piper methysticum) on c-DNA-expressed cytochrome P450 enzymes and human cryopreserved hepatocytes. Phytomedicine: 2004; 11 285 294
138. Unger M, Holzgrabe U, Jacobsen W, Cummins C, Benet LZ. Inhibition of cytochrome P450 3A4 by extracts and kavalactones of Piper methysticum (Kava-Kava). Planta Med: 2002; 68 1055 1058
139. Almeida JC, Grimsley EW. Coma from the health food store: interaction between kava and alprazolam. Ann Intern Med: 1996; 125 940 941
140. Teschke R, Schulze J. Risk of kava hepatotoxicity and the FDA consumer advisory. JAMA: 2010; 304 2174 2175
141. Teschke R, Qiu SX, Xuan TD, Lebot V. Kava and kava hepatotoxicity: Requirements for novel experimental, ethnobotanical and clinical studies based on a review of the evidence. Phytother Res: 2011; 25 1263 1274
142. Jones BD, Runikis AM. Interaction of ginseng with phenelzine. J Clin Psychopharmacol: 1987; 7 201 202
143. Galluzzi S, Zanetti O, Binetti G, Trabucchi M, Frisoni GB. Coma in a patient with Alzheimers disease taking low dose trazodone and Gingko biloba. J Neurol Neurosurg Psychiatry: 2000; 68 679 680
144. Gharagozloo M, Moayedi B, Zakerinia M, Hamidi M, Karimi M, Maracy M, Amirghofran Z. Combined therapy of silymarin and desferrioxamine in patients with beta-thalassemia major: a randomized double-blind clinical trial. Fundam Clin Pharmacol: 2009; 23 359 365
145. Aslam M, Stockley IH. Interaction between curry ingredient (karela) and drug (chlorpropamide). Lancet: 1979; 1 607
146. Heacock PM, Hertzler SR, Williams JA, Wolf BW. Effects of a medical food containing an herbal alpha-glucosidase inhibitor on postprandial glycemia and insulinemia in healthy adults. J Am Diet Assoc: 2005; 105 65 71
147. Panlasigui LN, Panlilio LM, Madrid JC. Glycaemic response in normal subjects to five different legumes commonly used in the Philippines. Int J Food Sci Nutr: 1995; 46 155 160
148. Dresser GK, Spence JD, Bailey DG. Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition. Clin Pharmacokinet: 2000; 38 41 57
149. US Food and Drug Administration Guidance for industry: Drug interaction studies-study design, data analysis and implications for dosing and labeling. Available at http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/UCM292362.pdf Accessed April 1, 2012
150. Zhao P, Rowland M, Huang SM. Best practice in the use of physiologically-based pharmacokinetic modeling and simulation to address clinical pharmacology regulatory questions. Clin Pharmacol Ther: 2012; 92 17 20
151. Fenneteau F, Poulin P, Nekka F. Physiologically based predictions of the impact of inhibition of intestinal and hepatic metabolism on human pharmacokinetics of CYP3A substrates. J Pharm Sci: 2010; 99 486 514
152. Na DH, Ji HY, Park EJ, Kim MS, Liu KH, Lee HS. Evaluation of metabolism-mediated herb-drug interactions. Arch Pharm Res: 2011; 34 1829 1842
153. Gurley BJ, Gardner SF, Hubbard MA, Williams DK, Gentry WB, Carrier J, Khan IA, Edwards DJ, Shah A. In vivo assessment of botanical supplementation on human cytochrome P450 phenotypes: Citrus aurantium, Echinacea purpurea, milk thistle, and saw palmetto. Clin Pharmacol Ther: 2004; 76 428 440
154. Markowitz JS, Devane CL, Chavin KD, Taylor RM, Ruan Y, Donovan JL. Effects of garlic (Allium sativum L.) supplementation on cytochrome P450 2D6 and 3A4 activity in healthy volunteers. Clin Pharmacol Ther: 2003; 74 170 177
155. Liu Z, Li Y, Li X, Ruan CC, Wang LJ, Sun GZ. The effects of dynamic changes of malonyl ginsenosides on evaluation and quality control of Panax ginseng C.A. Meyer. J Pharm Biomed Anal: 2012; 64-65 56 63
156. Muth M, Domanico J, Anderson D, Siegel P, Bloch L. Dietary supplement sales information final report. RTI project number 6673.004. Available at http://vm.cfsan.fda.gov/~acrobat/ds-sales.pdf Accessed February 10, 2012
157. US Food and Drug Administration Current Good Manufacturing Practice in manufacturing, packaging, labeling, or holding operations for dietary supplements. Available at http://gpo.gov/fdsys/pkg/FR-2007-06-25/html/07-3039. htm Accessed June 10, 2012
158. US Food and Drug Administration Federal Register Interim Final Rule 72 FR 34959: Petition to request an exemption from 100 percent identity testing of dietary ingredients: Current good manufacturing practice in manufacturing, packaging, labeling, or holding operations for dietary supplements. Available at http://www.fda.gov/Food/DietarySupplements/ GuidanceComplianceRegulatoryInformation/RegulationsLaws/ucm079573.htm Accessed June 10, 2012
159. Godtel-Armbrust U, Metzger A, Kroll U, Kelber O, Wojnowski L. Variability in PXR-mediated induction of CYP3A4 by commercial preparations and dry extracts of St. Johns wort. Naunyn Schmiedebergs Arch Pharmacol: 2007; 375 377 382
160. Mai I, Bauer S, Perloff ES, Johne A, Uehleke B, Frank B, Budde K, Roots I. Hyperforin content determines the magnitude of the St Johns wort-cyclosporine drug interaction. Clin Pharmacol Ther: 2004; 76 330 340
161. Mueller SC, Majcher-Peszynska J, Uehleke B, Klammt S, Mundkowski RG, Miekisch W, Sievers H, Bauer S, Frank B, Kundt G, Drewelow B. The extent of induction of CYP3A by St. Johns wort varies among products and is linked to hyperforin dose. Eur J Clin Pharmacol: 2006; 62 29 36
162. Mueller SC, Majcher-Peszynska J, Mundkowski RG, Uehleke B, Klammt S, Sievers H, Lehnfeld R, Frank B, Thurow K, Kundt G, Drewelow B. No clinically relevant CYP3A induction after St. Johns wort with low hyperforin content in healthy volunteers. Eur J Clin Pharmacol: 2009; 65 81 87
163. Vlachojannis J, Cameron M, Chrubasik S. Drug interactions with St. Johns wort products. Pharmacol Res: 2011; 63 254 256
164. Huang SM, Hall SD, Watkins P, Love LA, Serabjit-Singh C, Betz JM, Hoffman FA, Honig P, Coates PM, Bull J, Chen ST, Kearns GL, Murray MD. Drug interactions with herbal products and grapefruit juice: a conference report. Clin Pharmacol Ther: 2004; 75 1 12
165. Venkataramanan R, Ramachandran V, Komoroski BJ, Zhang S, Schiff PL, Strom SC. Milk thistle, a herbal supplement, decreases the activity of CYP3A4 and uridine diphosphoglucuronosyl transferase in human hepatocyte cultures. Drug Metab Dispos: 2000; 28 1270 1273
166. Zuber R, Modriansky M, Dvorak Z, Rohovsky P, Ulrichova J, Simanek V, Anzenbacher P. Effect of silybin and its congeners on human liver microsomal cytochrome P450 activities. Phytother Res: 2002; 16 632 638
167. Brantley SJ, Oberlies NH, Kroll DJ, Paine MF. Two flavonolignans from milk thistle (Silybum marianum) inhibit CYP2C9-mediated warfarin metabolism at clinically achievable concentrations. J Pharmacol Exp Ther: 2010; 332 1081 1087
168. Fuhr U, Beckmann-Knopp S, Jetter A, Luck H, Mengs U. The effect of silymarin on oral nifedipine pharmacokinetics. Planta Med: 2007; 73 1429 1435
169. Han Y, Guo D, Chen Y, Chen Y, Tan ZR, Zhou HH. Effect of silymarin on the pharmacokinetics of losartan and its active metabolite E-3174 in healthy Chinese volunteers. Eur J Clin Pharmacol: 2009; 65 585 591
170. Zhang S, Morris ME. Effects of the flavonoids biochanin A, morin, phloretin, and silymarin on P-glycoprotein-mediated transport. J Pharmacol Exp Ther: 2003; 304 1258 1267
171. Zhang S, Yang X, Morris ME. Flavonoids are inhibitors of breast cancer resistance protein (ABCG2)-mediated transport. Mol Pharmacol: 2004; 65 1208 1216
172. Deng JW, Shon JH, Shin HJ, Park SJ, Yeo CW, Zhou HH, Song IS, Shin JG. Effect of silymarin supplement on the pharmacokinetics of rosuvastatin. Pharm Res: 2008; 25 1807 1814
173. Gurley BJ, Barone GW, Williams DK, Carrier J, Breen P, Yates CR, Song PF, Hubbard MA, Tong Y, Cheboyina S. Effect of milk thistle (Silybum marianum) and black cohosh (Cimicifuga racemosa) supplementation on digoxin pharmacokinetics in humans. Drug Metab Dispos: 2006; 34 69 74
174. DiCenzo R, Shelton M, Jordan K, Koval C, Forrest A, Reichman R, Morse G. Coadministration of milk thistle and indinavir in healthy subjects. Pharmacotherapy: 2003; 23 866 870
175. Piscitelli SC, Formentini E, Burstein AH, Alfaro R, Jagannatha S, Falloon J. Effect of milk thistle on the pharmacokinetics of indinavir in healthy volunteers. Pharmacotherapy: 2002; 22 551 556
176. Mills E, Wilson K, Clarke M, Foster B, Walker S, Rachlis B, DeGroot N, Montori VM, Gold W, Phillips E, Myers S, Gallicano K. Milk thistle and indinavir: a randomized controlled pharmacokinetics study and meta-analysis. Eur J Clin Pharmacol: 2005; 61 1 7
177. Rao BN, Srinivas M, Kumar YS, Rao YM. Effect of silymarin on the oral bioavailability of ranitidine in healthy human volunteers. Drug Metabol Drug Interact: 2007; 22 175 185
178. Rajnarayana K, Reddy MS, Vidyasagar J, Krishna DR. Study on the influence of silymarin pretreatment on metabolism and disposition of metronidazole. Arzneimittelforschung: 2004; 54 109 113
179. Abenavoli L, Capasso R, Milic N, Capasso F. Milk thistle in liver diseases: past, present, future. Phytother Res: 2010; 24 1423 1432
180. Kroll DJ, Shaw HS, Oberlies NH. Milk thistle nomenclature: why it matters in cancer research and pharmacokinetic studies. Integr Cancer Ther: 2007; 6 110 119
181. Schrieber SJ, Wen Z, Vourvahis M, Smith PC, Fried MW, Kashuba AD, Hawke RL. The pharmacokinetics of silymarin is altered in patients with hepatitis C virus and nonalcoholic fatty liver disease and correlates with plasma caspase-3/7 activity. Drug Metab Dispos: 2008; 36 1909 1916
182. Gorski JC, Huang SM, Pinto A, Hamman MA, Hilligoss JK, Zaheer NA, Desai M, Miller M, Hall SD. The effect of echinacea (Echinacea purpurea root) on cytochrome P450 activity in vivo. Clin Pharmacol Ther: 2004; 75 89 100
183. Xie HG, Kim RB. St Johns wort-associated drug interactions: short-term inhibition and long-term induction? Clin Pharmacol Ther: 2005; 78 19 24
184. Markowitz JS, Devane CL, Boulton DW, Carson SW, Nahas Z, Risch SC. Effect of St. Johns wort (Hypericum perforatum) on cytochrome P-450 2D6 and 3A4 activity in healthy volunteers. Life Sci: 2000; 66 L133 L139
185. Imai H, Kotegawa T, Tsutsumi K, Morimoto T, Eshima N, Nakano S, Ohashi K. The recovery time-course of CYP3A after induction by St Johns wort administration. Br J Clin Pharmacol: 2008; 65 701 707
186. Dresser GK, Schwarz UI, Wilkinson GR, Kim RB. Coordinate induction of both cytochrome P4503A and MDR1 by St Johns wort in healthy subjects. Clin Pharmacol Ther: 2003; 73 41 50
187. Hu M, Wang DQ, Xiao YJ, Mak VW, Tomlinson B. Herb-drug interactions: methods to identify potential influence of genetic variations in genes encoding drug metabolizing enzymes and drug transporters. Curr Pharm Biotechnol: 2012; 13 1718 1730
188. Yin OQ, Tomlinson B, Waye MM, Chow AH, Chow MS. Pharmacogenetics and herb-drug interactions: experience with Ginkgo biloba and omeprazole. Pharmacogenetics: 2004; 14 841 850
189. Dietary Supplement Health and Education Act of 1994 (DSHEA). Available at http://www.fda.gov/RegulatoryInformation/Legislation/ FederalFoodDrugandCosmeticActFDCAct/SignificantAmendmentstotheFDCAct/ucm148003. htm Accessed January 29, 2012
190. Dietary Supplement and Nonprescription Drug Consumer Protection Act. Available at http://www.gpo.gov/fdsys/pkg/PLAW-109publ462/pdf/PLAW-109publ462. pdf Accessed June 10, 2012
191. US Food and Drug Administration Requirements on the content and format of labeling for human prescription drug and biological products. Available at http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/ LawsActsandRules/ucm084159.htm Accessed June 12, 2012
192. US Food and Drug Administration Center for Drug Evaluation and Research Guidance for industry-Botanical drug products. Available at http://www.fda.gov/ dowloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm070491.pdf Accessed February 10, 2012
193. Wu KM, Dou J, Ghantous H, Chen S, Bigger A, Birnkrant D. Current regulatory perspectives on genotoxicity testing for botanical drug product development in the U.S.A. Regul Toxicol Pharmacol: 2010; 56 1 3
194. De Castro WV, Mertens-Talcott S, Rubner A, Butterweck V, Derendorf H. Variation of flavonoids and furanocoumarins in grapefruit juices: a potential source of variability in grapefruit juice-drug interaction studies. J Agric Food Chem: 2006; 54 249 255
195. Woelkart K, Feizlmayr E, Dittrich P, Beubler E, Pinl F, Suter A, Bauer R. Pharmacokinetics of bilobalide, ginkgolide A and B after administration of three different Ginkgo biloba L. preparations in humans. Phytother Res: 2010; 24 445 450
196. Ding S, Dudley E, Plummer S, Tang J, Newton RP, Brenton AG. Quantitative determination of major active components in Ginkgo biloba dietary supplements by liquid chromatography/mass spectrometry. Rapid Commun Mass Spectrom: 2006; 20 2753 2760
197. Kim KA, Park PW, Park JY. Short-term effect of quercetin on the pharmacokinetics of fexofenadine, a substrate of P-glycoprotein, in healthy volunteers. Eur J Clin Pharmacol: 2009; 65 609 614
198. Han Y, Guo D, Chen Y, Tan ZR, Zhou HH. Effect of continuous silymarin administration on oral talinolol pharmacokinetics in healthy volunteers. Xenobiotica: 2009; 39 694 699
199. Penzak SR, Robertson SM, Hunt JD, Chairez C, Malati CY, Alfaro RM, Stevenson JM, Kovacs JA. Echinacea purpurea significantly induces cytochrome P450 3A activity but does not alter lopinavir-ritonavir exposure in healthy subjects. Pharmacotherapy: 2010; 30 797 805
200. Lilja JJ, Kivisto KT, Neuvonen PJ. Grapefruit juice-simvastatin interaction: effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors. Clin Pharmacol Ther: 1998; 64 477 483
201. Merck & Co. ZOCOR (simvastatin) Tablets. Drug label. Available at http://www.accessdata.fda.gov/drugsatfda-docs/label/2012/019766s085lbl.pdf Accessed April 1, 2012
202. Tapaninen T, Neuvonen PJ, Niemi M. Grapefruit juice greatly reduces the plasma concentrations of the OATP2B1 and CYP3A4 substrate aliskiren. Clin Pharmacol Ther 2010; 88: 339-342